formosanin c has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, P; Huang, Q; Liu, S; Wang, H; Xiao, J; Xiao, X; Yang, F; Yang, K; Yang, M; Zhang, B; Zou, J | 1 |
| Bai, P; Liu, S; Wang, H; Xiao, X; Yang, M; Zhu, H; Zou, J | 1 |
2 other study(ies) available for formosanin c and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Diosgenin; Female; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Diosgenin; Electrophoretic Mobility Shift Assay; Female; Heterografts; Humans; Immunohistochemistry; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Ovarian Neoplasms; Saponins; Signal Transduction | 2015 |